Filing Flows › Impact Biomedical (IBO) › Q3 2026 › vs Q3 2025
Impact Biomedical (IBO) Q3 2026 vs Q3 2025 (year over year)
Impact Biomedical's revenue rose $3K (+17%) from $18K in Q3 2025 to $21K in Q3 2026.
Impact Biomedical, Q3 2026: revenue $21K (+17% year over year), net loss $644K, operating cash flow $11K. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $21K | $18K | $3K | +17% |
| Other income, net | $4K | −$527K | $531K | — |
| Net loss | $644K | $1.5M | −$831K | -56% |
| Costs & expenses | $669K | $1.5M | −$824K | -55% |
| Operating costs | $669K | $966K | −$297K | -31% |
| Cost of revenue | $6K | $1K | $5K | +500% |
| Research & development | $35K | $52K | −$17K | -33% |
| SG&A | $156K | $261K | −$105K | -40% |
| Other operating costs | $472K | $652K | −$180K | -28% |
| Operating cash sources | $655K | $861K | −$206K | -24% |
| Depreciation & amortization | $284K | $288K | −$4K | -1% |
| Working capital & other | $371K | $573K | −$202K | -35% |
| Net loss absorbed | $644K | $1.5M | −$831K | -56% |
| Operating cash flow | $11K | −$613K | $624K | — |
Questions
How much did Impact Biomedical's revenue grow year over year in Q3 2026?
Impact Biomedical's revenue rose $3K (+17%) from $18K in Q3 2025 to $21K in Q3 2026.